Next Article in Journal
Characteristic of a Distant Relative of Teseptimavirus Genus Phages That Acquired the Ability to Lysogenize Its Host
Previous Article in Journal
Effect of N:K Ratio and Electrical Conductivity of Nutrient Solution on Growth and Yield of Hydroponically Grown Golden Thistle (Scolymus hispanicus L.)
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Cell Surface-Expressed GPI-Anchored Peptides from the CHR Domain of gp41 Are Potent Inhibitors of HIV-1 Fusion †

by
Aleksandra Maslennikova
1,*,
Dmitriy Komkov
1,
Anastasia Zotova
1 and
Dmitriy Mazurov
1,2
1
Cell and Gene Technology Group, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology RAS, Moscow 119334, Russia
2
NRC Institute of Immunology FMBA of Russia, Moscow 115478, Russia
*
Author to whom correspondence should be addressed.
Presented at Viruses 2020 - Novel Concepts in Virology, Barcelona, Spain, 5–7 February 2020.
Proceedings 2020, 50(1), 70; https://doi.org/10.3390/proceedings2020050070
Published: 16 June 2020
(This article belongs to the Proceedings of Viruses 2020—Novel Concepts in Virology)

Abstract

:
Current antiretroviral therapy efficiently suppresses viral replication but cannot eliminate latent HIV reservoirs. Moreover, the associated high costs, side effects, and drug resistance have stimulated a need for the development of alternative methods of HIV-1/AIDS treatment, such as peptide inhibitors or gene editing. Recently, we have developed Surface Oligopeptide knock-in for Rapid Target Selection (SORTS), a method for the rapid selection of CRISPR/Cas9 gene-edited cells via knock-in of the Flag and HA epitope tags embedded into the shortest GPI-protein, CD52. By targeting the capsid region of the HIV-1 genome, we demonstrate that SORTS can be applied in provirus eradication. However, the cells with inactivated provirus will be susceptible to HIV re-infection. We hypothesized that knocking in one of the peptides from the CHR-domain of gp41, which are known potent inhibitors of HIV-1 fusion, instead of the epitope tag, will provide “post-curable” HIV-1 resistance. While these peptides were extensively studied as soluble substances, their inhibitory effects on HIV after expression on cell surfaces via GPI-anchor are largely unknown. In this study, we established HEK293T/CD4/R5 and Raji/CD4/R5 HIV-1 permissive cell lines that stably expressed one of the gp41 peptides C34, MT-C34, MT-C34-R, and MT34-15D, or alfa-helix mimetics HP23L, p52, and MT-WQ-IDL. For cell surface delivery, the indicated peptides were embedded into the CD52 molecule, and upstream GFP was used to select transformed cells. Using a single-cycle replication assay with the inLuc reporter vector and different Envs, we demonstrated that C34-based GPI-anchored peptides inhibited both cell-free and cell-to-cell HIV-1 infection by at least two orders of magnitude. With the exception of HP23L, the alfa-helix mimetics were less potent inhibitors. Thus, peptides from gp41 associated with lipid rafts and exerted a strong inhibitory activity which can far exceed that determined for soluble peptides, but this should be tested further.

Funding

This work was supported by grant RFBR 18-29-07052 and by grant 075-15-2019-1661 from the Ministry of Science and Higher Education of the Russian Federation.

Share and Cite

MDPI and ACS Style

Maslennikova, A.; Komkov, D.; Zotova, A.; Mazurov, D. Cell Surface-Expressed GPI-Anchored Peptides from the CHR Domain of gp41 Are Potent Inhibitors of HIV-1 Fusion. Proceedings 2020, 50, 70. https://doi.org/10.3390/proceedings2020050070

AMA Style

Maslennikova A, Komkov D, Zotova A, Mazurov D. Cell Surface-Expressed GPI-Anchored Peptides from the CHR Domain of gp41 Are Potent Inhibitors of HIV-1 Fusion. Proceedings. 2020; 50(1):70. https://doi.org/10.3390/proceedings2020050070

Chicago/Turabian Style

Maslennikova, Aleksandra, Dmitriy Komkov, Anastasia Zotova, and Dmitriy Mazurov. 2020. "Cell Surface-Expressed GPI-Anchored Peptides from the CHR Domain of gp41 Are Potent Inhibitors of HIV-1 Fusion" Proceedings 50, no. 1: 70. https://doi.org/10.3390/proceedings2020050070

Article Metrics

Back to TopTop